Patents by Inventor Jeffrey Kurz

Jeffrey Kurz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMERSIVE VIRTUAL DISPLAY
    Publication number: 20240078770
    Abstract: A VR system for vehicles that may implement methods that address problems with vehicles in motion that may result in motion sickness for passengers. The VR system may provide virtual views that match visual cues with the physical motions that a passenger experiences. The VR system may provide immersive VR experiences by replacing the view of the real world with virtual environments. Active vehicle systems and/or vehicle control systems may be integrated with the VR system to provide physical effects with the virtual experiences. The virtual environments may be altered to accommodate a passenger upon determining that the passenger is prone to or is exhibiting signs of motion sickness.
    Type: Application
    Filed: September 12, 2023
    Publication date: March 7, 2024
    Applicant: Apple Inc.
    Inventors: Mark B. Rober, Sawyer I. Cohen, Daniel Kurz, Tobias Holl, Benjamin B. Lyon, Peter Georg Meier, Jeffrey M. Riepling, Holly Gerhard
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Patent number: 11913000
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: February 27, 2024
    Assignee: IVERIC bio, Inc.
    Inventors: Claude Benedict, David Epstein, Charles Wilson, Dilara McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman
  • APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS
    Publication number: 20210332361
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Application
    Filed: March 12, 2021
    Publication date: October 28, 2021
    Applicant: ARCHEMIX LLC
    Inventors: Claude Benedict, David Epstein, Charles Wilson, Dilara McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Patent number: 10947544
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: March 16, 2021
    Assignee: Archemix LLC
    Inventors: Claude Benedict, David Epstein, Charles Wilson, Dilara McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman
  • APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS
    Publication number: 20190185858
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 20, 2019
    Applicant: ARCHEMIX LLC
    Inventors: CLAUDE BENEDICT, DAVID EPSTEIN, CHARLES WILSON, DILARA MCCAULEY, JEFFREY KURZ, MARKUS KURZ, THOMAS GREENE MCCAULEY, JAMES ROTTMAN
  • APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS
    Publication number: 20180030446
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Application
    Filed: March 2, 2017
    Publication date: February 1, 2018
    Applicant: ARCHEMIX LLC
    Inventors: Claude BENEDICT, David EPSTEIN, Charles WILSON, Dilara MCCAULEY, Jeffrey KURZ, Markus KURZ, Thomas Greene MCCAULEY, James ROTTMAN
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Patent number: 9617546
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: April 11, 2017
    Assignee: Archemix LLC
    Inventors: Claude Benedict, David Epstein, Charles Wilson, Dilara McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman
  • Aptamer Therapeutics Useful in the Treatment of Complement-Related Disorders
    Publication number: 20150159158
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Application
    Filed: December 17, 2014
    Publication date: June 11, 2015
    Inventors: Claude Benedict, David Epstein, Charles Wilson, Dilara McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Patent number: 8946184
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: February 3, 2015
    Assignee: Archemix LLC
    Inventors: Claude Benedict, David Epstein, Charles Wilson, Dilara McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman
  • Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
    Patent number: 8598327
    Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: December 3, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Robert Schaub, Kathleen McGinness, Jennifer Nelson, Ryan Genga, Emily Waters, Jeffrey Kurz, John Diener
  • APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS
    Publication number: 20130237589
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Application
    Filed: March 4, 2013
    Publication date: September 12, 2013
    Applicant: ARCHEMIX LLC
    Inventors: Claude BENEDICT, David Epstein, Charles Wilson, Dilara McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman
  • Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder thereapeutics
    Patent number: 8461318
    Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: June 11, 2013
    Assignees: Baxter International Inc., Baxter Healthcare S.A.
    Inventors: Robert Schaub, Kathleen McGinness, Jennifer Nelson, Ryan Genga, Emily Waters, Jeffrey Kurz, John Diener
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Patent number: 8436164
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Grant
    Filed: June 18, 2012
    Date of Patent: May 7, 2013
    Assignee: Archemix LLC
    Inventors: Claude Benedict, David Epstein, Charles Wilson, Dilara McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman
  • APTAMER THERAPEUTICS USEFUL IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS
    Publication number: 20120322860
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Application
    Filed: June 18, 2012
    Publication date: December 20, 2012
    Applicant: ARCHEMIX LLC
    Inventors: CLAUDE BENEDICT, DAVID EPSTEIN, CHARLES WILSON, DILARA MCCAULEY, JEFFREY KURZ, MARKUS KURZ, THOMAS GREENE MCCAULEY, JAMES ROTTMAN
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Patent number: 8236773
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: August 7, 2012
    Assignee: Archemix LLC
    Inventors: Claude Benedict, David Epstein, Charles Wilson, Dilara McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman
  • APTAMERS TO TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE AS BLEEDING DISORDER THEREAPEUTICS
    Publication number: 20120190834
    Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.
    Type: Application
    Filed: November 3, 2011
    Publication date: July 26, 2012
    Applicants: Baxter International Inc.
    Inventors: Robert Schaub, Kathleen McGinness, Jennifer Nelson, Ryan Genga, Emily Waters, Jeffrey Kurz, John Diener
  • APTAMERS TO TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE AS BLEEDING DISORDER THERAPEUTICS
    Publication number: 20110281938
    Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.
    Type: Application
    Filed: February 11, 2011
    Publication date: November 17, 2011
    Applicants: Baxter Healthcare S.A., Baxter International Inc.
    Inventors: Robert Schaub, Kathleen McGinness, Jennifer Nelson, Ryan Genga, Emily Waters, Jeffrey Kurz, John Diener
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Patent number: 7803931
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Grant
    Filed: February 14, 2005
    Date of Patent: September 28, 2010
    Assignee: Archemix Corp.
    Inventors: Claude Benedict, John Diener, David Epstein, Dilara Grate, Sara Chesworth Keene, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman, Kristin Thompson, Charles Wilson, Anna J. Zoltoski
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Patent number: 7579456
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: August 25, 2009
    Assignee: Archemix Corp.
    Inventors: Claude Benedict, David Epstein, Dilârâ McCauley, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman, Charles Wilson
  • Aptamer therapeutics useful in the treatment of complement-related disorders
    Patent number: 7538211
    Abstract: The invention provides nucleic acid therapeutics and methods for using these nucleic acid therapeutics in the treatment of complement-related disorders.
    Type: Grant
    Filed: December 22, 2005
    Date of Patent: May 26, 2009
    Assignee: Archemix Corp.
    Inventors: Claude Benedict, John Diener, David Epstein, Dilara Grate, Sara Chesworth Keene, Jeffrey Kurz, Markus Kurz, Thomas Greene McCauley, James Rottman, Kristin Thompson, Charles Wilson, Anna J. Zoltoski